Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. van Wijk FH, et al. Among authors: namer m. Ann Oncol. 2003 Mar;14(3):441-8. doi: 10.1093/annonc/mdg112. Ann Oncol. 2003. PMID: 12598351 Free article. Clinical Trial.
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
Duffaud F, van der Burg ME, Namer M, Vergote I, Willemse PHB, ten Bokkel Huinink W, Guastalla JP, Nooij, Kerbrat P, Piccart M, Tumolo S, Favalli G, van der Vange N, Lacave AJ, Wils J, Splinter TA, Einhorn N, Roozendaal KJ, Rosso R, Vermorken JB. Duffaud F, et al. Among authors: namer m. Anticancer Drugs. 2001 Feb;12(2):159-62. doi: 10.1097/00001813-200102000-00010. Anticancer Drugs. 2001. PMID: 11261890 Clinical Trial.
Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix.
van Luijk IF, Coens C, van der Burg ME, Kobierska A, Namer M, Lhomme C, Zola P, Zanetta G, Vermorken JB; Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer. van Luijk IF, et al. Among authors: namer m. Ann Oncol. 2007 Feb;18(2):275-81. doi: 10.1093/annonc/mdl384. Epub 2006 Oct 23. Ann Oncol. 2007. PMID: 17060485 Free article. Clinical Trial.
Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
Guastalla JP, Lhomme C, Kerbrat P, Mayer F, Namer M, Goupil P, Charrot P, Heron JF, Chazard M, Richard I, et al. Guastalla JP, et al. Among authors: namer m. Ann Oncol. 1994 Feb;5(2):127-32. doi: 10.1093/oxfordjournals.annonc.a058763. Ann Oncol. 1994. PMID: 8186155 Free article. Clinical Trial.
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Wagenaar HC, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, Lacave AJ, van Hoesel Q, Cervantes A, Bolis G, Namer M, Lhommé C, Guastalla JP, Nooij MA, Poveda A, Scotto di Palumbo V, Vermorken JB. Wagenaar HC, et al. Among authors: namer m. Gynecol Oncol. 2001 Jun;81(3):348-54. doi: 10.1006/gyno.2001.6180. Gynecol Oncol. 2001. PMID: 11371121 Clinical Trial.
Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.
de Oliveira CF, Lacave AJ, Villani C, Wolff JP, di Re F, Namer M, Maskens A, George M, Dalesio O, Rotmensz N, et al. de Oliveira CF, et al. Among authors: namer m. Eur J Gynaecol Oncol. 1990;11(5):323-30. Eur J Gynaecol Oncol. 1990. PMID: 2097149 Clinical Trial.
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buyse M, Pouillart P. Diéras V, et al. Among authors: namer m. J Clin Oncol. 2004 Dec 15;22(24):4958-65. doi: 10.1200/JCO.2004.02.122. J Clin Oncol. 2004. PMID: 15611510 Clinical Trial.
237 results